Purchase this article with an account.
Nevin El-Nimri, Christine Frances Wildsoet; Effect of Topical Latanoprost on Myopia Progression in Guinea Pigs. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5469.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine, using the guinea pig form deprivation myopia model, whether ocular hypotensive prostaglandin analogs, which are very effective in reducing intraocular pressure (IOP) in humans, can also slow myopia progression.
Young guinea pigs underwent monocular form deprivation (FD; white plastic diffusers) from 14-days of age for 12-weeks. After the first week, FD eyes also received daily topical A) latanoprost (Lat, 0.005%, n=4) or B) vehicle (Veh; artificial tears; n=4). Weekly tonometry (iCare), retinoscopy and high frequency A-scan ultrasonography were undertaken to monitor IOP as well as refractive error and ocular axial dimensions (recorded as spherical equivalent values and optical axial lengths respectively). Additional IOPs were recorded at 6 h intervals, both at baseline and monthly, to examine diurnal IOP variations.
Lat both reduced IOP and slowed myopia progression relative to the vehicle treatment. Mean interocular IOP differences (± SD) changes from baseline values of -0.58± 0.94 mmHg (Veh) and -1.25± 1.1 mmHg (Lat) to 0.56± 1.34 mmHg (Veh) and -7.11± 3.66 mmHg (Lat) at 12 weeks. Interocular optical axial length differences changed from -0.01±0.04 to 0.22± 0.13 mm (Veh) and -0.05±0.06 to -0.01±0.05 mm (Lat), and interocular refractive error differences changed from 0.81± 1.46 to -8.5± 0.70 D (Veh) and -0.44±1.1 to 0.5±1.06 D (Lat). IOP fluctuations (maximum-minimum) appeared to be lower and less variable in FD Lat eyes compared to FD Veh eyes (8.78± 1.21 mmHg (Lat) vs. 11.92± 4.50 mmHg (veh), although not significantly so (p=0.26).
The results demonstrate that daily topical latanoprost is effective in both lowering IOP and slowing myopia progression in FD eyes of young guinea pigs. This result contrasts with those with the ocular hypotensive drug, timolol, a beta-blocker, which was shown in previous studies to be relatively ineffective in slowing myopia progression in chicks and humans.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only